IP Library Granted Patent US 7,919,125
Granted Patent B2
US 7,919,125 · App. 12/755,533 · Granted Apr 5, 2011

Modulation of inflammation by hops fractions and derivatives

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,919,125
App. No.
12/755,533
Granted
Apr 5, 2011
Kind
B2
Abstract

A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandin selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops.

Claims (4)

1. A method of treating a pathological condition associated with prostaglandins (PGs) production in a mammal, the method comprising inhibition of inducibility or activity of cyclooxygenase 2 (COX2) by administering to the mammal an effective amount of a composition comprising about 50 to 7500 mg of a compound selected from the group consisting of dihydro-isohumulone, dihydro-isocohumulone, dihydro-isoadhumulone, tetrahydro-isohumulone, tetrahydro-isocohumulone, tetrahydro-isoadhumulone, hexahydro-isohumulone, hexahydro-isocohumulone, and hexahydro-isoadhumulone; wherein the pathological condition is swelling after injury, migraine headache, or other inflammation-associated disorders.

2. The method of claim 1 , wherein the compound selected from the group consisting of dihydro-isohumulone, dihydro-isocohumulone, dihydro-isoadhumulone, tetrahydro-isohumulone, tetrahydro-isocohumulone, tetrahydro-isoadhumulone, hexahydro-isohumulone, hexahydro-isocohumulone, and hexahydro-isoadhumulonc is derived from hops.

3. The method of claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier.

4. The method of claim 1 wherein the composition is administered orally, topically, parenterally, or rectally.

Assignments (2)
SECURITY AGREEMENT Recorded Sep 8, 2010
From: META PROTEOMICS, LLC
To: BANK OF AMERICA, N.A.
Reel/Frame 024957/0394 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2010
From: TRIPP, MATTHEW L.; BABISH, JOHN G.; BLAND, JEFFREY S.; DARLAND, GARY K.; LERMAN, ROBERT; LUKACZER, DANIEL O.; LISKA, DEANN J.; HOWELL, TERRENCE
To: METAPROTEOMICS, LLC
Reel/Frame 024197/0810 →